Medtronic touts economic analysis of CGM use in Type II diabetes

Medtronic (NYSE:MDT) touted data today from an economic analysis evaluating the use of professional continuous glucose monitoring in people with Type II diabetes.

Data from the study, which the company called the first of its kind, showed significant cost avoidance to the healthcare system when CGM was used during a therapy change or when used at least twice per year.

Get the full story at our sister site, Drug Delivery Business News.

The post Medtronic touts economic analysis of CGM use in Type II diabetes appeared first on MassDevice.

from MassDevice http://ift.tt/2h7Nde9